Summary
Introduction
related, sharing a common α subunit and 30% identity in their β subunits. FT and GGTI (known as the CaaX prenylases) both recognize the tetrapeptide motif CaaX at the C terminus of their Modern target-based drug discovery begins with the development of highly potent in vitro agonists or antagonists of a dissubstrates and modify a single cysteine residue. Their substrates are then further processed by the CaaX endoprotease ease-associated target. However, agents that appear to have exquisite specificity for their target often yield unexpected bioand the isoprenylcysteine carboxyl methyltransferase (ICMT) (Clarke, 1992) . Since GGTI modifies essential cellular proteins logical activities. For example, compounds inhibiting farnesyl transferase (FT) have been developed as anticancer agents on such as the Rho family of GTPases (Bishop and Hall, 2000) , the development of FTIs has focused on selectivity for FT over the premise that they should block transforming Ras activity by inhibiting Ras prenylation and membrane association. While GGTI (for example, see Bell et al., 2002; Hunt et al., 2000) . In contrast, the third eukaryotic protein prenylase RabGGT the FTIs have shown promise in the clinic, the heterogeneity of responses seen in vivo and lack of correlation to Ras function appeared so distinct from the CaaX prenylases that its potential for interaction with the therapeutic FTIs was considered to suggests several mechanisms of therapeutic action (reviewed by Head and Johnston, 2003) . The role of other proteins that be low. Like FT and GGTI, RabGGT functions as a heterodimer. The α subunit has 27% identity to that of the CaaX prenylases require farnesylation has come under increasing scrutiny (Prendergast and Rane, 2001 ). However, the potential role of but contains additional domains, while the β subunit shows 29% identity to that of FT. The protein substrates of RabGGT other direct molecular targets of the compounds has not received widespread attention.
have heterogeneous C termini that usually contain two cysteine residues (CXC), both of which are modified by geranylgeranyl Eukaryotic cells possess two other prenyl transferases, geranylgeranyl transferase I (GGTI) and Rab geranylgeranyl transgroups without any subsequent processing steps. Unlike the CaaX prenylases, RabGGT requires specific accessory proferase (RabGGT or GGTII). FT and GGTI are the most closely
S I G N I F I C A N C E
FTIs were designed to treat tumors by inhibiting the function of the farnesyl transferase (FT) substrate Ras; however, they have activity on cancer cells and tumors that do not contain activated Ras, suggesting additional mechanisms. Using a chemical genetics approach, we have identified the enzyme RabGGT as an additional direct target of several proapoptotic FTIs, and demonstrated that loss of RabGGT function triggers p53-independent apoptosis. These findings will impact the interpretation of in vivo efficacy and toxicity studies of clinical FTIs, and may facilitate patient selection. Our results also point to the development of a new generation of anticancer agents specifically targeting RabGGT. teins known as REPs to guide the interaction with its targets 1B). While untreated wild-type adult worms contained at most two apoptotic corpses/gonad, with an average of less than (reviewed by Seabra, 2000) . Despite these differences, the one, worms treated with BMS1 at 0.8 mM had at least two three prenylases have strikingly similar active sites (Strickland corpses and an average of over six (Table 2A ). The effect of et al., 1998; and mechanisms of substrate BMS1 was similar in degree and appearance to that of RNA modification (Long et al., 2002) . The RabGGT substrates ideninterference (RNAi) directed against ced-9, a C. elegans homotified to date are all members of a family of >60 Ras-related log of the antiapoptotic protein Bcl-2 (Table 2A ). The relatively proteins called Rabs. These monomeric GTPases regulate inhigh dose of compound required is consistent with other tracellular membrane traffic, and their prenylation is usually studies (R.M.K., unpublished; Lewis et al., 1980) , and may be essential for correct targeting and function (reviewed by Dedue to the worm's protective cuticle. Induction of apoptosis by neka et al., 2003) . New work linking levels of Rab25 to the BMS1 was dose-dependent (Supplemental Figure S1 ). Comaggressiveness of epithelial cancers is the first direct evidence pounds BMS2 and BMS3 were also found to increase the level that they play an important role in carcinogenesis (Cheng et of germline apoptosis, whereas BMS4 had a very minor effect al., 2004).
( Figure 2A ; Table 2A ). Thus, the observations from a mammaDuring the development of small molecule FTIs at Bristollian cellular apoptosis assay were recapitulated in the C. eleMyers Squibb, several compounds were observed to possess gans assay. This correlation persisted for a further series of 8 a proapoptotic activity that did not correlate with their potency against either FT or GGTI (Rose et al., 2001) . Using the nematode Caenorhabditis elegans, we undertook a chemical genetics approach to clarify their mechanism of action. These FTIs were found to be proapoptotic in C. elegans, which is a wellvalidated system for studying apoptosis (reviewed by Gartner et al., 2000; Stergiou and Hengartner, 2004) . Similar proapoptotic effects were produced in C. elegans by targeted knockdown of components of the RabGGT complex and specific members of the Rab family. Additional biochemical and genetic tests established that the proapoptotic activity of these compounds in nematodes and in human cancer cells is related to their inhibition of RabGGT, and implicated this enzyme for the first time in cancer and apoptosis.
Results

Proapoptotic activity of FT inhibitors in C. elegans
As germ cells in C. elegans progress through meiosis and differentiation to become mature oocytes, some cells undergo programmed cell death (apoptosis) as part of normal development (Gumienny et al., 1999) . Although up to 300 oocytes may undergo apoptosis over the life of the animal, the cell corpses are rarely seen in wild-type worms. Since germ cells are com- petent to undergo apoptosis and can be visualized in an intact Nomarski images of the gonad arm region in a one-to two-day-old worm, animal, the number of corpses provides a sensitive and accuoriented with the distal region of the gonad to the top. Germ cells proceed in a clockwise direction as they mature. White arrowheads indicate examrate indicator for apoptotic modulators. differing potencies in a mammalian apoptosis assay (Table 1; B: Wild-type worm, exposed to BMS1 (1.6 mM) for 16 hr. Several corpses are present in the distal region.
assays as described by Rose et al. [2001] ) were selected for 41 encodes a 901 amino acid protein that is orthologous to yeast Vps41 (29% identical and 54% similar over 179 amino Proapoptotic effects are p53-independent but require a functional caspase pathway acids) and human VPS41 (28% identical and 50% similar over 842 amino acids). In Saccharomyces cerevisiae, Vps41 is reIn addition to developmentally programmed apoptosis, germ cells in C. elegans can undergo DNA damage-induced apoptoquired for sorting of proteins to the vacuole/lysosome, specifically for the step of endosomes and autophagosomes docking sis through a conserved checkpoint pathway that requires p53 function (Derry et al., 2001; Gartner et al., 2000; Schumacher to lysosomes prior to vesicle fusion (Nakamura et al., 1997) . C. elegans VPS-41 contains both the clathrin heavy chain reet al., 2001) . No reduction of the proapoptotic effect of BMS1 was observed upon treatment of a p53 deletion (cep-1) mutant peat and the RING-H2 zinc finger domains present in human VPS41. The ep402 allele was found to be a nonsense mutation strain of C. elegans (Table 2B ), indicating that the compound action was p53-independent.
that truncated both these domains. In addition to the forward-genetic approach, RNAi treatment To investigate whether the apoptotic effects of the BMS compounds in C. elegans were mediated via the canonical caswas used to screen for genes for which a reduction of function caused an increase in germline apoptosis in a cep-1 deletion pase pathway, compound BMS1 was applied to worms carrying mutations in either ced-3 (caspase) or ced-4 (APAF1). While background. We used a focused set of RNAi reagents comprising 2,636 genes that included the majority of kinases, phostreatment of wild-type worms with BMS1 increased the number of corpses to an average of over six per arm, no increase phatases, proteases, and nonolfactory G protein-coupled receptors encoded in the C. elegans genome. Since we had in corpses was observed when the ced-3 or ced-4 mutants were treated (Table 2B ). This suggests that the corpses obidentified the C. elegans homolog of VPS41 in the previous screen, indicating that endosome-lysosome protein sorting or served in BMS1-treated worms were derived via the established apoptotic mechanism.
autophagy (degradation of cytoplasmic proteins and organelles) may play a role in apoptosis, we also screened RNAi reaAn observed increase in apoptotic corpses could be due to either a defect in the apoptosis process itself or to a failure to gents for a set of 70 C. elegans genes that were related to genes implicated in lysosomal trafficking and/or autophagy in engulf and clear the apoptotic corpses from the gonad (reviewed by Hengartner, 2001 ). We examined the gonad arm reyeast. From this panel of 2706 genes, we identified 18 genes for which RNAi knockdown resulted in elevated levels of germgion in a worm strain carrying both the ced-1 and ced-10 mutations, leading to absence of engulfment. The corpses in this line apoptosis. Several of these genes will be described elsewhere. Although the effect of the RNAi treatment varied in penstrain showed a characteristic vacuolated morphology that was distinct from that of corpses produced by RNAi against etrance and expressivity from gene to gene, in each case, the proapoptotic effects were seen in both wild-type and p53 muced-9 (Bcl-2), and they accumulated in the proximal region of the gonad arm ( Figure 1C ), where they persisted indefinitely.
tant backgrounds, and were ced-3/caspase-and ced-4/ APAF1-dependent (data not shown). Because apoptotic reguSince the corpses in BMS compound-treated worms were not concentrated in the distal region and did not appear vacuolators of interest were to be validated in a mammalian cellautonomous system (as shown in Figure 4 ), they were not riglated ( Figure 1B) , and disappeared over time (data not shown), the compound-induced increase in the number of corpses was orously tested for effects on the C. elegans-specific engulfment and disposal pathways. However, in each case, it was oblikely due to an increase in apoptosis per se, rather than a failure to engulf the corpses that arise.
served that the phenotype did not resemble existing engulfment mutants (compare Figures 1C and 1D ). Among the genes that most strongly induced apoptosis in Genetic screens implicate Rab Proteins and RabGGT in apoptosis this RNAi knockdown screen, we noted orthologs encoding the five proteins (Vps11, Vps16, Vps18, Vps33, Vps39; Table 2C ) In parallel with our studies using compounds, EMS mutagenesis and RNA interference (RNAi) screens were conducted to that combine with Vps41 to form the HOPS complex in yeast. The HOPS complex interacts with the GTPase Rab7, and toidentify key mediators of germline apoptosis in C. elegans. Since we were interested in regulators that act in the absence gether they are required to drive endosome-lysosome and autophagosome-lysosome docking and fusion (Seals et al., of a functional p53 protein (which is mutated in many cancers; Slee et al., 2004), we looked for genes whose inactivation re-2000). Inactivation of the C. elegans ortholog of RAB7, rab-7, also led to high levels of germline apoptosis (Table 2C ). Howsulted in an increase in the number of apoptotic cells in a cep-1 deletion mutant.
ever, RNAi of homologs of yeast autophagy-specific genes did not induce germline apoptosis, suggesting that endosomeIn a forward genetic approach, approximately 58,000 F2 and 100,000 F1 EMS-mutagenized genomes were screened, and lysosome function was of primary relevance. We examined the effect of inactivating the 28 other Rab family members idenfour loci were identified. For the mutant that showed the strongest increase in germline apoptosis, ep402, adults typitified in the C. elegans genome. Only RNAi of rab-7 and rab-5 (the single C. elegans ortholog of the human RAB5A, RAB5B, cally displayed >20 apoptotic corpses per gonad arm ( Figure  1D ). ep402 also caused phenotypes not associated with apoand RAB5C genes) was found to induce germline apoptosis (Table 2C ). Rab5 and Rab7 share a function in protein traffickptosis, including maternal-effect embryonic lethality and partially penetrant larval arrest. The increased apoptosis in the ing from early endosomes to late endosomes. RNAi against the single C. elegans ortholog of the mammalian Rab guanine ep402 mutant was p53-independent, but was blocked by a ced-4/APAF1 loss-of-function mutation (data not shown). Monucleotide dissociation inhibitors GDI1 and GDI2, which are positive regulators of Rab function, also induced high levels of lecular genetic analysis revealed that the predicted genes germline apoptosis (Table 2D) . Next, we examined inactivation an IC 90 of 10 M ( Figure 3A and Table 1 ). BMS1 has been tested at 8 M or higher on 69 other pharmaceutical targets of the enzyme responsible for prenylation of the Rab GTPases.
with no inhibition of activity, indicating that its action on RNAi directed against mRNA for either the C. elegans
RabGGT is specific. RabGGT-α or RabGGT-β subunit was effective at inducing
To further investigate the occurrence of dual inhibition and germline apoptosis. In contrast, RNAi treatment directed its relationship to the proapoptotic activity, an additional 19 poagainst C. elegans genes encoding either the FT-β or GGTI-β tent FTI compounds (FT IC 50 for H-ras <20 nM) were evaluated subunit, the α subunit shared by FT and GGTI, or other compoin both assays. The majority of these FTIs were found to also nents of the CaaX processing system, did not result in ininhibit RabGGT: 14 compounds had IC 50 values below 100 nM, creased apoptosis in this assay (Table 2D ). The finding that a and the IC 50 s ranged from 8 nM to >15 M. These observareduction of RabGGT expression caused increased apoptosis, tions further supported a relationship between the potency of in conjunction with the known functional and structural similaria compound for inhibition of RabGGT (IC 90 ) and its ability to ties between this enzyme and FT, led us to consider that induce apoptosis ( Figure 3B ; R 2 = 0.76). To extend these obRabGGT could be a target of the proapoptotic FTI compounds servations, 12 FTIs with a RabGGT IC 90 range of 58 to 570 nM BMS1, BMS2, and BMS3.
were tested for apoptotic activity across eight further cell lines, including the p53-negative PC3 and MLF lines. In general, the Synergistic effect of compound treatment compounds induced apoptosis at submicromolar concentrawith loss of RabGGT tions, with the least potent RabGGT inhibitor also being the We examined the effect of a low dose of BMS1 (0.3 mM) on least potent apoptotic agent (Supplemental Table S1 ; R 2 > 0.54 the level of apoptosis caused by a reduction in RabGGT exfor seven lines). In contrast, no relationship between potency against FT and apoptotic activity was observed for these compression. The experimental rationale is that the effect of a subpounds (Supplemental Table S1 ; R 2 < 0.23). maximal compound dose will be potentiated if the target's acTo investigate whether cellular activity against RabGGT octivity is already partially compromised. RNAi directed against curs at doses relevant to the proapoptotic effects of comthe α subunit of RabGGT (RabGGT-a RNAi) induced a lower pounds, the A549 human lung cancer cell line was treated with level of germline apoptosis than RNAi directed against the β compounds BMS1 and BMS4. Cellular inhibition of RabGGT subunit ( Figure 2B , Table 2E ), suggesting that it reduced but and FT was detected by the cytoplasmic accumulation of undid not eliminate RabGGT activity. Therefore, RabGGT-a RNAi prenylated Rab5B or unprenylated H-Ras, respectively. Both was used to produce a partial loss of RabGGT function in adult BMS compounds maximally inhibited H-Ras prenylation at the worms. Table 2E contains data for each treatment administered lowest dose used ( Figure 3C ). In the same extracts, accumulaindividually and in combination with compound. Coadministration of unprenylated Rab5B in BMS1-treated cells was evident tion of the RabGGT-a RNAi reagent with BMS1 at 0.3 mM at the 0.5 M dose and increased at the 1M dose, while for caused an increase in the level of apoptosis that was substan-BMS4 no accumulation relative to control treatment was aptially greater than the additive value of the independent treatparent at doses up to 5 M ( Figure 3C ). To determine whether ments: the fraction of gonad arms with more than 4 corpses apoptosis was induced by these treatments, activation of casincreased to 88%, from 9% with the RNAi treatment alone or pase-3/7 was monitored by the appearance of a luminescent 17% with the low dose of compound alone. No such synergy cleavage product. Staurosporine treatment was included as a was seen between compound treatment and a control RNAi positive control. Caspase activation was induced by BMS1 at treatment of an unrelated target that produced a similar level both 0.5 M and 1 M, but was not seen with BMS 4 at doses of apoptosis (Table 2E , Figure 2C ). Thus, a specific hypersensiup to 5 M ( Figure 3D ). The observation of a >10-fold differtivity to the compound was observed when RabGGT expresence between the cellular potency of BMS1 and BMS4 for both sion was reduced.
RabGGT inhibition and induction of caspase activity supports a relationship between these properties. These assays also reiterate the lack of relationship between potency against FT and Direct inhibition of RabGGT activity apoptotic activity for these compounds. by the FTI compounds The synergism of the FTI compounds with RNAi against Targeting RabGGT by siRNA induces apoptosis RabGGT was suggestive of compound inhibition of RabGGT in mammalian cancer cell lines activity. We examined this possibility by using an in vitro assay If inactivation of RabGGT by compounds BMS1, BMS2, and that reconstituted the prenylation of Rab3A by RabGGT. The BMS3 is a source of their proapoptotic activity in mammalian proapoptotic compounds BMS1, BMS2, and BMS3 were found cancer cells, then a reduction of RabGGT function by other to be highly potent inhibitors of mammalian RabGGT, with IC 50 means should also induce apoptosis. We induced degradation values of 16-36 nM. Compound BMS4 was up to 33-fold less of RabGGT mRNA using small interfering RNAs (siRNA), and potent, with an IC 50 of 541 nM. Thus, there was an agreement examined the effects on apoptotic status of cancer cell lines. between the relative activity of these compounds in apoptosis For each RabGGT subunit, two effective siRNAs were selected assays and their inhibition of RabGGT activity in vitro (Table 1) .
(Supplemental Figures S2 and S3 ). An siRNA targeting the casDose response curves differed, which is relevant if it is necespase regulator XIAP was also used, providing a benchmark for sary to completely eliminate the function of RabGGT to proinduction of apoptosis. siRNAs against both α and β subunits duce apoptosis. For example, compound BMS1 had an IC 90 were antiproliferative (Supplemental Figure S4 ). Apoptotic status was evaluated both by measurement of apoptotic indivalue of 200 nM, whereas BMS4 was 50-fold less potent, with 
cators in cancer cell populations and by direct observation of
RabGGT mRNA is overexpressed in a subset of human tumors individual cells.
Using quantitative reverse transcription-polymerase chain reFirst, activation of caspase-3/7 was monitored by the apaction analysis (qRT-PCR), we measured expression of the pearance of a luminescent cleavage product after siRNAs were
RabGGT-a and -b subunits in 9 different tumor types: breast, introduced into A549 cells. RabGGT-specific siRNAs produced colon, head and neck, kidney, lung, melanoma, ovary, prostate, significant increases in signal over the background values for and uterine. Matched normal samples were assayed for 169 of cells transfected with a control siRNA ( Figure 4A ). The inducthe 194 tumor specimens. We found that both RabGGT-a and tion of caspase 3/7 activity by RabGGT siRNAs was comparaRabGGT-b were expressed abundantly in all tissues examined. ble to that of the XIAP control, and could be reversed by coRabGGT-b showed significant overexpression relative to nortreatment with the caspase inhibitor Z-VAD-FMK ( Figure 4A ). mal tissue in ovarian tumors, adenocarcinomas of the colon, Second, the occurrence of cytoplasmic histone-associated large cell lung carcinomas, and melanomas (Kruskal-Wallis DNA fragments (a feature of apoptosis; Salgame et al., 1997) , rank statistical analysis with p < 0.05; Figure 5 ). RabGGT-a was assayed after the siRNAs were introduced into the A2780 transcripts were also significantly elevated in ovarian tumors human ovarian carcinoma cell line. The siRNAs to RabGGT and melanomas (p < 0.05; data not shown). produced a significant signal in this assay, while cells transDiscussion fected with a control siRNA had the expected background signal ( Figure 4C ). Finally, activation of caspase 3, nuclear conIn this work, the nematode C. elegans was used as a surrogate densation, and proliferation was quantified at two timepoints genetic system to identify the mammalian target responsible in individual cells of the p53 null prostate cancer cell line PC3
for the proapoptotic activity of a number of compounds that (Supplemental Tables S2-S4 ). Activated caspase 3 was seen had been optimized for inhibition of FT. After establishing that in a substantial proportion of cells; the effect of RabGGT loss the compounds were also proapoptotic in C. elegans, we was stronger than that of the positive control XIAP ( Figure 4C) . noted a similarity between this compound-induced phenotype Increased nuclear condensation was seen with siRNAs against and that produced by RNAi of a class of genes identified in a RabGGT and the XIAP control ( Figures 4D-4G) , with highly genetic screen. This class encodes proteins involved in vesicucompact nuclei found in caspase-positive cells (Figures 4F and lar trafficking, and most notably the prenyltransferase RabGGT, 4G). In summary, the positive results seen for several apoptotic which is responsible for geranylgeranylation of the Rab family parameters in three different cell lines demonstrate that a reof small GTPases. In worms, the proapoptotic effect of the duction in RabGGT function can be sufficient to induce cancer compounds is synergistic with a reduction in RabGGT function. Extending our observations from C. elegans, we demonstrated cell lines to undergo p53-independent apoptosis. that the compounds inhibit mammalian RabGGT activity in vitations in C. elegans, suggesting a key role for this organelle in tro and in cells with high potency. Cellular inhibition of Rab the induction of apoptosis. Endosomal Rab GTPases have very prenylation was evident at doses that induce apoptosis, and recently been connected to apoptosis and proliferation of cansiRNA against RabGGT was sufficient to induce apoptosis in cer cells (Cheng et al., 2004) . Our screens identified all known three human cancer cell lines. Finally, the RabGGT-a and -b members of the HOPS complex, which acts with Rab7 to regugenes are overexpressed in ovarian tumors and melanomas. In late endosomal fusion events. We found that knockdown of summary, our experimental results illustrate the use of pharmathe C. elegans Rab GDI also induced high levels of germline cological, biochemical, and genetic methods that have conapoptosis, presumably by blocking recycling of GDP-bound verged upon a single enzyme. These approaches have idenRab proteins from acceptor vesicle membranes back to donor tified a novel pathway for p53-independent induction of membranes (Pfeffer et al., 1995) . The apoptotic function of apoptosis, and suggest that blocking the posttranslational RabGGT is likely linked to its role in allowing proper membrane modification of Rab proteins is a source of the proapoptotic localization of the GTPases Rab5 and Rab7, and possibly other activity of some FTIs.
Rab family members in mammals. Interestingly, the proapoptotic effect of the FTI compound L-744,832 has been demonInvolvement of the endosomal trafficking strated to require Amphiphysin II (Bin1; DuHadaway et al., pathway in apoptosis 2003), a protein that functions in endocytosis and is predicted Regulation of endosomal-lysosomal trafficking emerged as a common theme from our genetic screens for proapoptotic muto interact with small GTPases.
of animals lacking cep-1/p53, we were able to identify potential drug targets that could have therapeutic benefits in treatment of p53− tumors. The enzyme RabGGT presents a chemically tractable new target for apoptotic induction in cancer cells. We show that expression of the genes encoding RabGGT subunits is elevated in certain tumor types, indicating that the enzyme may play a functional role in cancer initiation or progression. The RabGGT enzyme structure has been determined, and its mechanism of substrate modification has been studied (Shen and Thoma et al., 2001a; Thoma et al., 2001b; . A recent study that identified structural factors influencing FTI compound specificity (Reid and Beese, 2004) will provide useful insights for RabGGT inhibitor development. Thus, there is an excellent foundation for a rational drug design approach. Only two compounds that affect RabGGT activity have previously been described, and neither shows a high degree of potency or specificity for RabGGT (Ren et al., 1997; Coxon et al. 2001 ). Our results demonstrate a strong 
cells. Interestingly, no broad proliferation or apoptotic effects
RabGGT-β mRNA levels were using qRT-PCR; asterisks indicate differential were described in mice whose RabGGT-α subunit is impaired expression relative to the corresponding normal tissue (p < 0.05 in the (Detter et al., 2000) , suggesting that tumor cells could be hyKruskal-Wallis rank statistical analysis). Filled box: normal tissue samples.
persensitive to the proapoptotic effects of enzyme inhibition. recycling in development of epithelial cancers (Cheng et al., 2004) . Our genetic screens in worms implicated the endosomal regulators Rab5 and Rab7 in apoptosis. Rab5 regulates transport from the plasma membrane to early endosomes and enHow does blocking endosomal-lysosomal trafficking induce dosome-endosome fusion, and has been implicated in growth apoptosis? We envision two general models. First, the lysocontrol in a number of studies. The Rab5 effector AAPL1 is some could act directly on established components of the essential for cellular proliferation (Miaczynska et al., 2004) , pathway. In support of this model, an antisense knockout of while the tumor suppressor gene TSC2 has been reported to the lysosomal protease cathepsin L lowers Bcl-2 expression act as a GAP for Rab5 (Xiao et al., 1997) and overexpression levels and triggers apoptosis in human glioma cell lines (Leviof the TSC2 GAP domain was found to suppress tumorigenesis car et al., 2003) . Similarly, we find that RNAi of the C. elegans (Jin et al., 1996; Momose et al., 2002) . In contrast, overexprescathepsin L ortholog, cpl-1, induces caspase-dependent sion of PRC17, also a Rab5 GAP, induces tumorigenesis in germline apoptosis (data not shown). Alternatively, perturbing nude mice (Pei et al., 2002) . Thus, the connection between the fusion of endosomes to lysosomes might indirectly induce GTP cycling by Rab5 and tumorigenesis is not yet clear. Rab7 apoptosis. In this model, rupture or leakage of accumulated, catalyzes late endosome-lysosome and homotypic (endounfused vesicles might release proapoptotic agents, such as some-endosome and lysosome-lysosome) fusion. Recently, ceramide or hydrolytic enzymes, into the cytoplasm. Edinger et al. (2003) found that an RNAi against Rab7 slightly improved the survival of a growth factor-deprived murine cell Identification of novel targets in cancer line. This discrepancy with the strongly proapoptotic effect of The identification of pro-and antiapoptotic target proteins is an rab-7 knockdown seen in C. elegans may be due to the difimportant area of pharmaceutical research (reviewed by Makin, ferent experimental endpoint. It is also possible that despite 2002). The work presented in this paper demonstrates that rethe good agreement between C. elegans and mammalian apoducing the levels of proteins in the HOPS complex or inhibiting ptosis assays that is seen for RabGGT, loss of Rab7 would the prenylation of the key regulatory GTPases Rab5 and Rab7 not induce apoptosis in a mammalian system. Overall, further leads to p53-independent induction of programmed cell death. studies of Rab5 and Rab7 function in cancer models will be p53 is frequently mutated in human tumors, and studies in a required to evaluate their utility as targets for cancer therapy. variety of species have indicated that induction of apoptosis (as opposed to cell cycle regulation) is the most conserved Implications for specificity of other FTIs function of p53 (reviewed by Slee et al., 2004) . By screening Our data provide the first demonstration of high-potency dual inhibition of RabGGT and FT. Thoma et al. had raised concerns for genes whose inactivation triggers apoptosis in the germline over FTI specificity upon noting that RabGGT can effectively ity, and may lead to the development of a new generation of agents specifically targeting RabGGT. bind and transfer farnesyl pyrophosphate (Thoma et al., 2000) .
Chemical genetics is most commonly framed as an openHowever, since the current generation of FTIs occupy the pepended program to create small molecule modulators of many tide binding site rather than competing for isoprenoid binding different proteins as research tools (Strausberg and Schreiber, (see Reid and Beese, 2004) , such crossreactivity had seemed 2003). Our work highlights the value of combining genetics and unlikely. Yet the peptide binding site also shows remarkable biochemistry in focused studies to elucidate the in vivo mechastructural conservation between the three protein prenyltransnism of single, well-characterized compounds. This approach ferases . Could the ability to crossreact be may identify novel regulatory mechanisms of important biologia general property of FTIs? Of the 23 FTIs tested in this study, cal processes, and also directly assists the development and 17 were found to be highly potent inhibitors of RabGGT, indiclinical use of the resulting drugs. We expect that such studies cating that crossreactivity is common but not universal. The 23 will become increasingly important as the standards imposed compounds have several similarities to clinical candidate FTIs.
on drug selectivity continue to rise, and as the use of pharmaThey are targeted to the peptide binding site by an imidazole cogenomic tools to match drug and patient becomes more ring that acts as a ligand for the zinc ion present in all three common. enzymes. Imidazole rings have been used for this purpose in several other FTIs in development, for example in Janssen's Experimental procedures R115777 (Venet et al., 2003) , in Abbott Laboratories' biphenyl FTI (Curtin et al., 2003) , in the original Merck clinical compound
Compound treatment and phenotypic analysis L-778,123 (Britten et al., 2001) , and in Merck's series of macroof C. elegans cyclic compounds (Bell et al., 2002) . Additionally, the com-
The compounds used in this study (Supplemental Figure S5 ) pounds we tested are predicted to share the common binding were dissolved in dimethyl sulfoxide (DMSO) and mixed with attributes identified by Reid and Beese in their study of six dead OP50 bacteria suspended in M9 buffer (Epstein and diverse clinical FTI candidates (Reid and Beese, 2004) . This Shakes, 1995) at a final DMSO concentration of 4%. This susstudy also noted that compound selectivity for FT over GGTI pension was applied to agar plates, which were then seeded does not depend on the peptide substrate specificity of each with 1-day-old adult worms. Apoptosis was quantified at 16 enzyme. Thus, the difference in RabGGT peptide substrate hr with high-resolution Nomarski optics. Corpses were readily specificity is not a barrier to crossreactivity by these FTIs. We distinguished by their compact, button-like appearance (Guhave found dual inhibition of FT and RabGGT by multiple commienny et al., 1999) . ced-3(n2433) and ced-4(n1162) were obpounds with diverse structures, indicating that it is not unusual tained from the CGC. for a compound to interact with both proteins. While our data indicate that the optimization of a compound for inhibition of Genetic mapping, cloning, and sequencing FT is not directly linked to potency against RabGGT, it is likely
The ep347 deletion allele of cep-1 was identified by standard that additional FTI compounds fortuitously also inhibit RabGGT.
PCR-based methods (Jansen et al., 1997) . ep347 removes exOur data suggest that the role of RabGGT inhibition in the mechaons 9-13 and blocks DNA-damage-induced apoptosis to a nism of action of other proapoptotic FTIs should be evaluated. similar extent as mutations in hus-1 and rad-5 (Supplemental Figure S6 ). The cep-1 (ep347) allele has this sequence across Implications for cancer therapy the deletion breakpoints: ACATTGATAATGTATCCAGGCGCAG/ This work demonstrates that compounds developed as FT in-CATCCAGGAAGCGATGAAACTGCCA. hibitors can also be potent inhibitors of RabGGT. These results Mutagenesis and characterization were according to Epstein have several important implications for the clinical developand Shakes (1995) . The recessive increased-germline apoptoment of FTI drugs, which were conceived as specific therapeusis (Gla) phenotype of the ep402 mutant cosegregated with a tics for Ras-related cancers. First, crossreactivity to a second recessive maternal effect lethal (Mel) phenotype. The Mel pheprotein target could explain why FTIs can show activity on tunotype was mapped relative to single nucleotide polymormors and cells that lack transforming Ras function. This discrepphisms between CB4586 and N2 (var. Bristol) (detected as deancy has provoked research that implicated other FT substrates scribed by Swan et al., 2002) to a 113 Kb interval between the such as RhoB (Du et al., 1999a) centromere associated proregions contained in cosmids Y34B4A and C26B9. RNAi teins (Ashar et al., 2000) , and most recently Rheb (Tee et al., against the 20 predicted genes in this interval produced a Gla 2003). Our data show that such research must also consider phenotype for only two: Y34B4A.1 and F32A6.3. Transcript activities beyond FT inhibition. Second, our demonstration that analysis showed that Y34B4A.1 and F32A6.3 represent a single inhibition of RabGGT function is proapoptotic may relate to the gene. ep402 is a nonsense mutation (UGG / UGA) at codon unexpected proapoptotic effects that have been reported for 523 in predicted exon 9 of F32A6.3. several FTIs (Du et al., 1999b; End et al., 2001; Jiang et al., 2000; Rose et al., 2001; Manne et al., 2004) . Finally, even low Treatment of worms with RNAi reagents potency against RabGGT could be relevant in an FTI treatment RNAi reagents were generated by PCR amplification from a setting where high local drug concentrations are achieved.
C. elegans genomic DNA template using LA Taq (Takara). Thus, our findings may explain and help to manage the doseGene-specific priming sequences (Supplemental Table S5 ) limiting toxicities that have emerged in clinical trials of these were flanked by the T7 polymerase priming site. Amplicons therapeutics (Head and Johnston, 2003) . Understanding the typically spanned at least 1 kb and comprised exons. RNA was mechanism of action of the FTIs will allow improvements in transcribed using the MEGAscript High Yield Transcription Kit (Ambion) and annealed at 68°C for 20 min. PCR product size patient selection and in monitoring of in vivo efficacy and toxic-and quality of double-stranded RNA (dsRNA) were confirmed tity units were calculated from a 5-point standard curve obtained using Universal Human Reference RNA (Stratagene). by gel electrophoresis. dsRNA was precipitated and resuspended in 20 mM KPO 4 , 3 mM potassium citrate, 2% PEG 6000. For RNAi treatment, 1 l of M9 buffer containing w50
Supplemental Data
L3 worms was added to 3 l of dsRNA (w5 mg/ml) and incuSupplemental Data are available online at http://www.cancercell.org/cgi/ bated for 24 hr in a sealed 96-well plate at 20°C, then plated content/full/7/4/325/DC1/.
on NGM plates seeded with OP50 bacteria for 24 hr before compound treatment and/or apoptosis assays.
